Verve Therapeutics Files 8-K: Material Agreement & Other Events
| Field | Detail |
|---|---|
| Company | Verve Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, exhibits
TL;DR
Verve Therapeutics signed a big deal, filed financials. Big news incoming.
AI Summary
On June 16, 2025, Verve Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The filing was made on June 17, 2025.
Why It Matters
This 8-K filing indicates Verve Therapeutics has entered into a significant agreement, which could impact its strategic direction and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their terms and implications for the company's operations and finances.
Key Players & Entities
- Verve Therapeutics, Inc. (company) — Registrant
- June 16, 2025 (date) — Date of earliest event reported
- June 17, 2025 (date) — Filing date
- 201 Brookline Avenue, Suite 601, Boston, Massachusetts 02215 (address) — Principal executive offices
FAQ
What type of material definitive agreement did Verve Therapeutics enter into?
The filing states Verve Therapeutics entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What are the 'Other Events' reported by Verve Therapeutics?
The filing mentions 'Other Events' as a category but does not detail what these events are in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 16, 2025.
What is Verve Therapeutics' principal executive office address?
Verve Therapeutics' principal executive offices are located at 201 Brookline Avenue, Suite 601, Boston, Massachusetts 02215.
What is the SEC file number for Verve Therapeutics?
The SEC file number for Verve Therapeutics is 001-40489.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Verve Therapeutics, Inc..